Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
Study Phase: Phase 3
Recruitment Status: Recruiting
Start Date: May 07, 2019
End Date: November 05, 2022
Inclusion Criteria:
- Informed consent obtained before any trial-related activity
- Completed the lead-in trial (ZP1848-17111) or completed the Phase 2 trial (ZP1848-15073)
Exclusion Criteria:
- Withdrawal of consent from the lead-in trial
- Any condition or disease or circumstance that in the Investigator's opinion would put the patient at any undue risk, prevent completion of the trial, or interfere with the analysis of the trial results
- Use of GLP-1, GLP-2, human growth hormone, somatostatin, or analogs thereof, within 3 months prior to Screening
- Females of childbearing potential, who are pregnant, breast-feeding, intend to become pregnant or are not using highly effective contraceptive methods
-
Conditions:
- Short Bowel Syndrome
- Syndrome